News | October 08, 2021
Lincoln Pharma gets Australian TGA approval
The company plans to expand its portfolio in regulated markets aggressively
The company plans to expand its portfolio in regulated markets aggressively
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
Since its inception, over three million users have used MFine services with the platform clocking over three lakh monthly transactions
One of the key factors driving the market growth is the rise in the occurrence of chronic cardiovascular diseases such as heart failure and coronary artery disease: Valuates Reports
The CAC solution cleared by the U.S. FDA analyses already existing non-gated CT scans and quantifies the coronary artery calcium in order to identify, stratify, and facilitate treatment pathways for patients with cardiovascular disease
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Subscribe To Our Newsletter & Stay Updated
